

New York State Medicaid Drug Utilization Review (DUR) Board Meeting
Room 3, Concourse Level, Empire State Plaza, Albany NY
May 16, 2024
10:00am to 4:00pm

The meeting will be available for public viewing as a live and archived webcast
[Department of Health Events and Webcasts](#)

10:00 – 10:15 Welcome and Introductions

10:15 – 11:45 Public Comment Period

11:45 – 1:00 Preferred Drug Program (PDP) Review

The DUR Board will review the therapeutic classes listed below, as they pertain to the PDP ([NYS Public Health Law, Sections 272 and 273](#)), and recommend drugs for preferred or non-preferred status. The review may also include revisions to clinical criteria or coverage parameters for the therapeutic class. The Preferred Drug List (PDL), which includes preferred or non-preferred status and clinical criteria, may be viewed at: [NYRx Preferred Drug List](#). For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information, which is new since the previous review of the therapeutic class and then consider financial information.

1. Movement Disorder Agents
Previous Review Date: 5/12/2022
2. Multiple Sclerosis Agents
Previous Review Date: 7/15/2021
3. Anti-Fungals - Topical
Previous Review Date: 5/12/2022
Drug(s) to be added to the therapeutic class: ciclopirox solution, Jublia (efinaconazole), tavaborole
4. Immunomodulators - Topical
Previous Review Date: 6/10/2009
Drug(s) to be added to the therapeutic class: Eucrisa (crisaborole) and Opzelura (ruxolitinib)
5. Anabolic Steroids - Topical
Previous Review Date: 9/17/2015
Drug(s) to be added to the therapeutic class: Natesto (testosterone)
6. Growth Hormones
Previous Review Date: 9/21/2023



- 7. Proton Pump Inhibitors (PPIs)
Previous Review Date: 5/18/2023
- 8. Hemophilia Agents - Factor VIII
Initial Review
- 9. Immunomodulators - Systemic
Previous Review Date: 5/18/2023
- 10. Anti-inflammatory/Immunomodulators - Ophthalmic
Previous Review Date: 5/13/2021
Drug(s) to be added to the therapeutic class: Eysuvis (loteprednol)
- 11. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) - Ophthalmic
Previous Review Date: 4/27/2017
- 12. Phosphate Binders/Regulators
Previous Review Date: 7/15/2021
- 13. Rosacea Agents - Topical*
Initial Review
Drug(s): azelaic acid, Finacea (azelaic acid), ivermectin, metronidazole, Noritate (metronidazole), Rosadan (metronidazole)

*Therapeutic class(es) not currently subject to the PDP

1:00 – 3:00 Lunch / Executive Session (PDP Financial Review)

3:00 – 3:45 PDP Recommendations

3:45 – 4:00 Final Comments and Adjournment

The agenda timeline is subject to change based on meeting proceedings.

Additional Information

Parties interested in providing public comments, during the DUR Board meeting, must complete the registration process by May 8, 2024. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes), and the total comment period will not exceed ninety (90) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

Written statements and clinical documents can be sent to dur@health.ny.gov. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included. Written statements and clinical documents must be received by May 2, 2024, to allow the DUR Board members ample time to review the information.

All information must be sent to the DOH. Stakeholders and interested parties should not contact or send any information directly to DUR Board members.

Other Meeting Locations

University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Abbott Hall Room 130
Buffalo, NY 14214

SUNY Global Center
Boardroom
116 East 55th Street, New York, NY 10022